Investigator

Yoshihiro Hayakawa

Professor · Univesity of Toyama, Institute of Natural Medicine

Research Interests

YHYoshihiro Hayakawa
Papers(1)
Dihydrocapsaicin Enha…
Collaborators(5)
Chantana BoonyaratHiroaki SakuraiPornthip WaiwutSureewan DuangjitTeeraporn Sadira Supa…
Institutions(3)
University Of ToyamaKhon Kaen UniversityUbon Ratchathani Univ…

Papers

Dihydrocapsaicin Enhances Tumor Necrosis Factor-α-Induced Apoptosis and G1 Cell Cycle Arrest in Human Cervical Cancer Cells Through TAK1-Mediated NF-κB and EGFR Pathways

Dihydrocapsaicin (DHC), a prominent capsaicinoid derived from red chili peppers, has shown cytotoxic effects against various cancer cell types. However, its role in modulating cytokine-induced survival and apoptotic signaling in cancer cells remains unclear. In this study, we investigated the effects of DHC on tumor necrosis factor-α (TNF-α)-induced cell cycle arrest and apoptosis in HeLa human cervical cancer cells. Our results demonstrate that DHC significantly enhances TNF-α-induced G1 phase cell cycle arrest and apoptosis by targeting the transforming growth factor-β-activated kinase 1 (TAK1)-mediated prosurvival pathways. DHC inhibited the phosphorylation of TAK1 and downstream effectors including IKKα, NF-κB p65, MAPKs (p38, JNK, ERK), Akt, and EGFR, thereby disrupting key signaling networks that typically confer resistance to TNF-α-induced cytotoxicity. Additionally, DHC suppressed the TNF-α-induced phosphorylation of EGFR at Ser-1046/1047 and Thr-669, sites critical for survival signaling. Co-treatment with DHC and TNF-α led to enhanced apoptotic features, including increased PARP-1 cleavage. These findings suggest that DHC sensitizes cervical cancer cells to cytokine-induced cell death by interfering with TAK1/NF-κB and EGFR signaling axes. Our study positions DHC as a promising candidate for combination therapies aimed at overcoming resistance in cancers with aberrant inflammatory and survival signaling.

170Works
1Papers
5Collaborators
Cell Line, TumorNeoplasmsNeoplasm MetastasisApoptosisTumor MicroenvironmentLung NeoplasmsTumor EscapeBreast Neoplasms

Positions

2017–

Professor

Univesity of Toyama · Institute of Natural Medicine

2012–

Associate Professor

University of Toyama · Institute of Natural Medicine

2009–

Associate Professor

University of Tokyo · Graduate School of Pharmaceutical Sciences

2007–

Research Fellow/Group Leader

Merck Research Laboratories Tsukuba · Pharmacology

2001–

Senior Research Officer

Peter MacCallum Cancer Centre · Cancer Immunology Program

2001–

Postdoc

Toyama Medical and Pharmaceutical University · Institute of Natural Medicine

Education

2001

Ph.D.

Toyama Medical and Pharmaceutical University · Graduate School of Pharmaceutical Sciences

1998

M.S.

Toyama Medical and Pharmaceutical University · Graduate School of Pharmaceutical Sciences

1996

Bc.S.

Toyama Medical and Pharmaceutical University · Faculty of Pharmaceutical Sciences